Thermo Fisher Scientific (TMO) consistently remains a point of interest for investors and Wall Street analysts. We see evidence of both bullish perspectives and concerns about tariff impacts affecting the company's future profits. It's noted that Veritas Asset Management LLP and Waverton Investment Management Ltd have significantly increased their TMO holdings. TMO has experienced a dip in stock performance but is regarded as an oversold stock to buy, a sentiment echoed by several billionaire investors. The first quarter of 2025 brought robust earnings, beating estimates and strong financial performance. Developments across diverse sectors include the launching of a sustainable centrifuge line, the opening of the Advanced Therapies Collaboration Center, and a significant partnership with Cybin for depression treatment. Despite a forecast for a decline in earnings, TMO announced a $2B investment to expand US operations. However, job cuts will occur at their Orlando location. The company faced some challenges, including tariffs, and profit forecast cuts. Committed to growth, innovation, and expanding their product line, TMO also declared an acquisition. Despite recent volatility, the long-term outlook remains positive.
Thermo Fisher Scientific TMO News Analytics from Thu, 07 Nov 2024 08:00:00 GMT to Sat, 17 May 2025 17:57:36 GMT -
Rating 4
- Innovation 7
- Rumor 2
